SLNO Soleno Therapeutics Inc

Soleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference

Soleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference

REDWOOD CITY, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will present at the 2024 Cantor Global Healthcare Conference on Tuesday, September 17, 2024, at 8:00 AM Eastern Time.

A live audio webcast and replay of the presentation will be available in the Investors section on the Company’s website at .

About Soleno Therapeutics, Inc.

Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. An NDA for its lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS) is currently under review by the FDA and was granted Priority Review. For more information, please visit .

Corporate Contact:

Brian Ritchie

LifeSci Advisors, LLC

212-915-2578



EN
16/09/2024

Underlying

SLNOSoleno Therapeutics Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Soleno Therapeutics Inc

 PRESS RELEASE
Free
SLNO Soleno Therapeu...

Soleno Therapeutics Announces Oral Presentations featuring Diazoxide C...

Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024 REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will be presenting data from its DCCR clinical development program for the treatment of Prader-Willi syndrome (PWS) at the 62nd Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2024, bein...

November 14, 2024 1 EN
 PRESS RELEASE
Free
SLNO Soleno Therapeu...

Soleno Therapeutics Provides Corporate Update and Reports Third Quarte...

Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results REDWOOD CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the third quarter ended September 30, 2024. Third Quarter 2024 and Recent Corporate Highlights New Drug Application (NDA) for DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi sy...

November 6, 2024 1 EN
 PRESS RELEASE
Free
SLNO Soleno Therapeu...

Soleno Therapeutics to Participate in Upcoming November Investor Confe...

Soleno Therapeutics to Participate in Upcoming November Investor Conferences REDWOOD CITY, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in the following upcoming investor conferences: Event: Guggenheim Healthcare Innovation Conference Date: Monday, November 11, 2024Time: 10:00 AM ET Event: Stifel 2024 Healthcare Conference Date: Monday, November 18, 2024 Time: 4:45 PM ET Even...

October 28, 2024 1 EN
 PRESS RELEASE
Free
SLNO Soleno Therapeu...

Soleno Therapeutics Announces the Passing of Former Chairman Ernest Ma...

Soleno Therapeutics Announces the Passing of Former Chairman Ernest Mario, Ph.D. REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced with deep sadness the passing of former Chairman of the Board of Directors, Ernest Mario, Ph.D, at the age of 86 years. Dr. Mario served as the Soleno’s (formerly Capnia’s) Chairman from 2007 through August 2024. "On behalf of the Board of Directors and the entire Soleno family,...

October 21, 2024 1 EN
 PRESS RELEASE
Free
SLNO Soleno Therapeu...

Soleno Therapeutics Announces Regulatory Update on DCCR (diazoxide cho...

Soleno Therapeutics Announces Regulatory Update on DCCR (diazoxide choline) Extended-Release Tablets to Treat Prader-Willi Syndrome REDWOOD CITY, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced a regulatory update from the U.S. Food and Drug Administration (FDA). The FDA Review Division has determined that there does not appear to be a need for an advisory committee meeting at this time for the New Drug Application (...

October 8, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch